Is Royalty Pharma plc overvalued?

Royalty Pharma plc (RPRX) looks overvalued — trading about 54% above its fair value.

Overvalued

Price

$58.21

Fair value

$26.85

Current P/E

32.3

Normal P/E

14.9

Market cap

$25.80B

Dividend yield

1.6%

Return on equity

12.3%

Sector

Healthcare

Fair value compares RPRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks